Peri-Transplant and Maintenance Daratumumab for Minimal Residual Disease (MRD) Eradication in Transplant-Eligible Multiple Myeloma (MM) Patients
Blood | November 28, 2022 | Volume: 140 | Issue: Supplement 1 | Pages: 10165-10166
10.1182/blood-2022-165209